Home        Sitemap        Contact us 
Multiple Cancer Indications
 
You are in: » Pipeline  » Targeted Therapeutics  » Oncology  » Multiple Cancer Indications
 
According to the National Cancer Institute's estimation approximately 11 million Americans with a history of cancer and about 1.53 million cancer cases are expected to be diagnosed in 2010 and the cancer is the second most common cause of death in the US. Overall costs of cancer in 2010 estimated to be $264 billion. Globally it is accounted for 7.4 million cases and the 5 year relative survival rate for all cancer types is 68%.

The human genome sequencing led to the identification of over 520 protein kinases and constitutes one of the largest classes of potential drug targets for the pharmaceutical industry and much attention has been devoted to the development for oncology therapeutics. ARRIEN is committed to discovering and developing innovative targeted therapeutics for the treatment of multiple cancer types through our integrated drug discovery activities on protein kinases for rapid advancement of compounds to IND. We established a unique portfolio of novel small molecules protein kinase inhibitors with high therapeutic benefit for treating pancreatic, breast, prostate, lung, colon and blood cancers and the clinical potential of the candidates which are of primary focus of the Arrien.

Arrien Pharmaceuticals is pursuing a number of drug targets for the treatment of different cancers particularly targeting protein kinases. The lead candidate belongs to a class of 3000 series Candidate Ready ARN-3261 currently in late stage pre-clinical/IND enabling studies for Ovarian, Breast, Prostate, Lung and DLBCL cancer indications and we expecting to enter into IND safety and toxicology studies by Q3 2017. Additionally, company is actively researching towards the development of other first-in-class pre-clinical stage Oncology programs utilizing the FFDD technology. Lead optimization/Medicinal Chemistry/SAR and candidate nomination stage of development is an ongoing work.
 
 
Copyright © 2011, Arrien Pharmaceuticals, LLC. All rights reserved.